Safety and PK Results From an Ongoing Phase I-II Study of ONA in Patients With PR-Expressing Cancers
Paul Cottu, MD, MSc, medical oncologist, Institut Curie, Paris, discusses safety and pharmacokinetic (PK) results from phase I of an ongoing phase I-II study of onapristone (ONA) in patients with progesterone receptor (PR)-expressing cancers.
